LENALIDOMIDE
lenalidomide 20 mg capsule, 21
LENALIDOMIDE (14631C)
14631C
Manner of administration:Oral
Restriction
Indication: Multiple myeloma
Treatment phase: Initial treatment with triple therapy (this drug, bortezomib and dexamethasone) for
the first 4 treatment cycles (cycles 1 to 4) administered in a 28-day treatment cycle
Quantities & Cost
| Max qty packs | Max qty units | # of repeats | DPMQ | Max safety net | General Patient Charge |
|---|---|---|---|---|---|
| Max qty packs: 1 | Max qty units: 21 | # of repeats: 3 | DPMQ: $796.93 | Max safety net: $25.00 | General Patient Charge: $25.00 |
| Available brands | |||||
|
|
|||||
|
|
|||||